Lupus & antiphospholipid syndrome
Treatment patterns and outcomes of first lupus nephritis episode over 25 years in two Latin American cohorts
Authors' conclusion
Patients in the contemporary cohort benefited from advances in treatment strategies, with less cumulative damage and progression to ESRD, although mortality remained unchanged.
Study context
- Population
- SLE patients with biopsy-confirmed first lupus nephritis (LN) episode, classified as non-proliferative (class V) or proliferative (classes III/IV), two Latin American cohorts over 25 years
- Participants
- 532 patients
- Exposure
- GLADEL 2.0 vs GLADEL 1.0
- GLADEL 2.0n = 170
- GLADEL 1.0n = 362reference
- Outcome
- Associations with four outcomes: mortality, damage accrual (SDI), hospitalization and end-stage renal disease (ESRD)
Methodological detailstwo Latin American cohorts (historical and contemporary), propensity score matching, logistic regression
- Two Latin American cohorts (historical and contemporary)
- Propensity score matching
- Logistic regression
Main finding
As reported in the abstract
- SDI associated with baseline SDI and glucocorticoids (GC) pulses; belonging to GLADEL 2.0 was protective
- Mortality associated with Mestizo ethnicity and partial health coverage; antimalarial protective
- Hospitalizations associated with baseline SLEDAI and SDI, follow-up time and lower educational level
- Belonging to GLADEL 2.0 protective against end-stage renal disease (ESRD)
Observational data: associations, not effects.
Further findings
Treatment patterns, GLADEL 2.0 vs GLADEL 1.0
- Lower doses of oral GC, more frequently GC pulses and antimalarials, less frequently CYC in GLADEL 2.0
- Increase in use of MMF and other immunosuppressants
Original publication
Treatment patterns and outcomes of first lupus nephritis episode over 25 years in two Latin American cohorts. Lupus. Published 28 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →